Currax Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Currax Pharmaceuticals's estimated annual revenue is currently $45.2M per year.
- Currax Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Currax Pharmaceuticals has 225 Employees.
- Currax Pharmaceuticals grew their employee count by 6% last year.
Currax Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head HR | Reveal Email/Phone |
3 | SVP, Corporate Development and Strategy | Reveal Email/Phone |
4 | VP Human Resources | Reveal Email/Phone |
5 | VP Sales | Reveal Email/Phone |
6 | VP, Information Technology Infrastructure | Reveal Email/Phone |
7 | VP, FP&A | Reveal Email/Phone |
8 | VP, Associate General Counsel | Reveal Email/Phone |
9 | Senior Director, Trade and Distribution | Reveal Email/Phone |
10 | Associate Director, Digital Marketing | Reveal Email/Phone |
Currax Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $6.6M | 33 | 32% | N/A | N/A |
#2 | $38M | 189 | 6% | N/A | N/A |
#3 | $6.6M | 33 | 22% | N/A | N/A |
#4 | $4180M | 15242 | 1% | $550M | N/A |
#5 | $17.5M | 87 | 50% | N/A | N/A |
#6 | $6.7M | 125 | -37% | $199.6M | N/A |
#7 | $10.9M | 54 | 15% | N/A | N/A |
#8 | $15.3M | 76 | 33% | N/A | N/A |
#9 | $128.6M | 640 | 16% | N/A | N/A |
#10 | $18.7M | 93 | 21% | N/A | N/A |
What Is Currax Pharmaceuticals?
Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the U.S. market.
keywords:N/AN/A
Total Funding
225
Number of Employees
$45.2M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $86.8M | 239 | 7% | N/A |
#2 | $15M | 242 | -2% | N/A |
#3 | $48.5M | 252 | 35% | N/A |
#4 | $15M | 261 | 5% | N/A |
#5 | $78.7M | 265 | 6% | N/A |